© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Evaxion Biotech A/S (EVAX) shows an Average True Range (ATR) of 0.49 and an Enterprise Value of 26.83M. Its average trading volume over the past 3 months is 363.18K, indicating liquidity. These fundamental metrics provide insight into EVAX's underlying financial health and market activity.
Evaxion Biotech A/S (EVAX) technical indicators as of January 1, 2026: the SMA 20 is -13.38%, SMA 50 at -15.27%, and SMA 200 at 36.28%. The RSI 14 value is 41.79, suggesting its current momentum. These technical analysis signals help assess EVAX's price trends and potential future movements.
Evaxion Biotech A/S (EVAX) stock performance overview as of January 1, 2026: The 52-week high is $12.15 (currently -60.74% below), and the 52-week low is $1.2 (currently 297.5% above). Over the past year, EVAX's performance is 6.71%, compared to the S&P 500's 12.29% change.
According to market data, Evaxion Biotech A/S (EVAX) stock's recent performance metrics show that over the last month, EVAX is -19.7%, with a Year-to-Date (YTD) performance of 12.77%. Over the past year, the stock has seen a 6.71% change. These figures summarize EVAX's price movements across various periods, reflecting its historical returns.
According to current financial data, EVAX stock's P/E (TTM) ratio is -8.69, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for EVAX, including P/S (9.37), P/B (16.72), and P/FCF (N/A), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.